A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
Не применимо
Прекращено
NCT05966740
| Заболевание | Venous Thromboembolism |
|---|
| Фаза | Не применимо |
|---|
| Спонсор | Boehringer Ingelheim |
|---|
| Статус | Прекращено |
|---|
| Участники | 5 участн. |
|---|
| Дата начала | 19.04.2024 |
|---|
| Дата завершения | 28.04.2025 |
|---|
| Публикация результатов | 2.06.2026 |
|---|
Кратко
The main research question of this study is to obtain further safety and effectiveness data on Pradaxa Pellets in children aged 3 months to less than 12 years in routine clinical practice setting.
Cumulative Incidence of Clinically Relevant Bleeding Events
From first Pradaxa Pellets exposure until its discontinuation plus 3 days of residual effect period, switch to other anticoagulation therapy, or planned observation time, whichever occurred first. Up to 373 days. · Participants
| Pradaxa-treated Patients | 1 Participants |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.